Last-Chance cancer drug access program opens for desperate patients
NCT ID NCT06132191
Summary
This program provides compassionate access to the immunotherapy drug cemiplimab for patients with advanced non-small cell lung cancer, basal cell carcinoma, or cutaneous squamous cell carcinoma. It's designed for individuals who have exhausted all other approved treatment options and cannot join standard clinical trials. Access is granted on a case-by-case basis and depends on location and specific patient circumstances.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER (NSCLC) are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.